English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Development of  Salmonella enterica  serovar Typhimurium ( S.  Typhimurium) live attenuated vaccine carrier strain to prevent enteric infections has been a subject of intensive study. Several mutants of  S . Typhimurium have been proposed as an effective live attenuated vaccine strain. Unfortunately, many such mutant strains failed to successfully complete the clinical trials as they were suboptimal in delivering effective safety and immunogenicity. However, it remained unclear, whether the existing live attenuated  S . Typhimurium strains can further be attenuated with improved safety and immune efficacy or not.    Results  We deleted a specific non-SPI (Salmonella Pathogenicity Island) encoded virulence factor  mig-14  (an antimicrobial peptide resistant protein) in  ssaV  deficient  S.  Typhimurium strain. The  ssaV  is an important SPI-II gene involved in  Salmonella  replication in macrophages and its mutant strain is considered as a potential live attenuated strain. However, fatal systemic infection was previously reported in immunocompromised mice like  Nos2  −/−  and  Il-10  −/−  when infected with  ssaV  deficient  S . Typhimurium. Here we reported that attenuation of  S . Typhimurium  ssaV  mutant in immunocompromised mice can further be improved by introducing additional deletion of gene  mig-14 . The  ssaV, mig-14  double mutant was as efficient as  ssaV  mutant, with respect to host colonization and eliciting  Salmonella -specific mucosal sIgA and serum IgG response in wild-type C57BL/6 mice. Interestingly, this double mutant did not show any systemic infection in immunocompromised mice.    Conclusions  This study suggests that  ssaV, mig-14  double mutant strain can be effectively used as a potential vaccine candidate even in immunocompromised mice. Such attenuated vaccine strain could possibly used for expression of heterologous antigens and thus for development of a polyvalent vaccine strain.

bmc microbiology

Salmonella Typhimurium TTSS-2 deficient mig-14 mutant shows attenuation in immunocompromised mice and offers protection against wild-type Salmonella Typhimurium infection